The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax
Alexandria P. Eiken(University of Nebraska Medical Center), Dalia El‐Gamal(University of Nebraska Medical Center)
Cited by 2
Related Papers
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
|Biomedicines|2021|30
Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects
|bioRxiv (Cold Spring Harbor Laboratory)|2024|0